---
figid: PMC7038792__401_2019_2029_Fig1_HTML
figlink: pmc/articles/PMC7038792/figure/Fig1/
number: F1
caption: NF2/merlin signaling and potential therapeutic targets in NF2. A schematic
  diagram depicts major intracellular pathways regulated by merlin, the protein product
  of the NF2 gene. Merlin is associated with the plasma membrane via its N-terminal
  FERM domain, where it interacts with adherens junctions and numerous cell surface
  receptors including integrins, receptor tyrosine kinases (RTK), and CD44. The C-terminal
  domain of merlin interacts with cytoskeletal actin filaments. Merlin has a predominantly
  inhibitory activity on downstream effectors including RAS, PI3K, RAC, and SRC, which
  may result in reduced downstream RAF/MEF/ERK, AKT/JNK/JUN, mTORC1, FAK, and RAC
  signaling. Merlin may inhibit translocation of β-catenin to the nucleus, reducing
  the output of canonical Wnt/β-catenin signaling. Merlin also interacts with the
  Hippo pathway by promoting MST1/2-mediated translocation of LATS1/2 to the nucleus
  as well as through inhibition of CRL4DCAF1, resulting in reduced transcriptional
  output of YAP/TAZ and TEA domain transcription factors (TEADs). In the nucleus,
  merlin may also inhibit the activity of LIN28A, thereby relieving inhibition of
  the let-7 miRNA cluster leading to downregulation of proto-oncogenic proteins such
  as MYC and RAS. Loss of function of merlin via pathogenic mutations in NF2 patients
  results in alteration of downstream activity in each of these pathways (red arrows
  indicate steps with possible increased activity following loss of merlin function,
  as in NF2-associated tumors), potentially leading to increased cell growth, protein
  and fatty acid synthesis, proliferation, and survival. A variety of therapeutic
  avenues have been explored in NF2 patients, including inhibition of proteins regulated
  by merlin as well as other cellular receptors. Inhibition of the RAF/MEK/ERK pathway
  via small molecule MEK inhibitors is currently being explored in clinical trials
  for NF2-associated tumors (NCT02639546, NCT03095248). A phase 2 clinical trial is
  exploring small molecule inhibition of FAK by GSK2256098 (NCT02523014/A071401) in
  NF2 mutant meningiomas. Small molecule mTOR inhibitors including everolimus and
  sirolimus have shown therapeutic promise in NF2-associated schwannomas and meningiomas,
  and additional compounds including RAD001 and AZD2014 are in clinical trials for
  the treatment of progressive/symptomatic NF2-associated meningiomas (NCT02831257)
  and recurrent high-grade (WHO grade II/III) meningiomas (NCT03071874), respectively.
  The VEGF inhibitor bevacizumab has shown clinical utility in NF2-associated schwannomas,
  meningiomas, and ependymomas. Inhibition of the tyrosine kinase receptors cMET and
  EGFR may provide additional therapeutic opportunities in NF2-associated meningiomas.
  Additional therapeutic targets have been proposed, including the immunomodulatory
  PD-1/PD-L1 axis, the chemokine receptor CXCR4, and Ephrin receptor A2 (EphA2)
pmcid: PMC7038792
papertitle: An update on the CNS manifestations of neurofibromatosis type 2.
reftext: Shannon Coy, et al. Acta Neuropathol. 2020;139(4):643-665.
pmc_ranked_result_index: '107785'
pathway_score: 0.9784812
filename: 401_2019_2029_Fig1_HTML.jpg
figtitle: NF2/merlin signaling and potential therapeutic targets in NF2
year: '2020'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7038792__401_2019_2029_Fig1_HTML.html
  '@type': Dataset
  description: NF2/merlin signaling and potential therapeutic targets in NF2. A schematic
    diagram depicts major intracellular pathways regulated by merlin, the protein
    product of the NF2 gene. Merlin is associated with the plasma membrane via its
    N-terminal FERM domain, where it interacts with adherens junctions and numerous
    cell surface receptors including integrins, receptor tyrosine kinases (RTK), and
    CD44. The C-terminal domain of merlin interacts with cytoskeletal actin filaments.
    Merlin has a predominantly inhibitory activity on downstream effectors including
    RAS, PI3K, RAC, and SRC, which may result in reduced downstream RAF/MEF/ERK, AKT/JNK/JUN,
    mTORC1, FAK, and RAC signaling. Merlin may inhibit translocation of β-catenin
    to the nucleus, reducing the output of canonical Wnt/β-catenin signaling. Merlin
    also interacts with the Hippo pathway by promoting MST1/2-mediated translocation
    of LATS1/2 to the nucleus as well as through inhibition of CRL4DCAF1, resulting
    in reduced transcriptional output of YAP/TAZ and TEA domain transcription factors
    (TEADs). In the nucleus, merlin may also inhibit the activity of LIN28A, thereby
    relieving inhibition of the let-7 miRNA cluster leading to downregulation of proto-oncogenic
    proteins such as MYC and RAS. Loss of function of merlin via pathogenic mutations
    in NF2 patients results in alteration of downstream activity in each of these
    pathways (red arrows indicate steps with possible increased activity following
    loss of merlin function, as in NF2-associated tumors), potentially leading to
    increased cell growth, protein and fatty acid synthesis, proliferation, and survival.
    A variety of therapeutic avenues have been explored in NF2 patients, including
    inhibition of proteins regulated by merlin as well as other cellular receptors.
    Inhibition of the RAF/MEK/ERK pathway via small molecule MEK inhibitors is currently
    being explored in clinical trials for NF2-associated tumors (NCT02639546, NCT03095248).
    A phase 2 clinical trial is exploring small molecule inhibition of FAK by GSK2256098
    (NCT02523014/A071401) in NF2 mutant meningiomas. Small molecule mTOR inhibitors
    including everolimus and sirolimus have shown therapeutic promise in NF2-associated
    schwannomas and meningiomas, and additional compounds including RAD001 and AZD2014
    are in clinical trials for the treatment of progressive/symptomatic NF2-associated
    meningiomas (NCT02831257) and recurrent high-grade (WHO grade II/III) meningiomas
    (NCT03071874), respectively. The VEGF inhibitor bevacizumab has shown clinical
    utility in NF2-associated schwannomas, meningiomas, and ependymomas. Inhibition
    of the tyrosine kinase receptors cMET and EGFR may provide additional therapeutic
    opportunities in NF2-associated meningiomas. Additional therapeutic targets have
    been proposed, including the immunomodulatory PD-1/PD-L1 axis, the chemokine receptor
    CXCR4, and Ephrin receptor A2 (EphA2)
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - VEGFD
  - VEGFB
  - PGF
  - VEGFA
  - VEGFC
  - PDCD1
  - CXCR4
  - EGFR
  - CD44
  - CD274
  - PRKACG
  - PRKAR1A
  - PRKAR2A
  - PRKAR2B
  - PRKACA
  - PRKACB
  - PRKAR1B
  - SRC
  - HRAS
  - KRAS
  - NRAS
  - PIK3CA
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3CB
  - PIK3CD
  - PIK3R5
  - PIK3R6
  - RHOG
  - RAC1
  - RAC2
  - RAC3
  - PTK2
  - ARAF
  - BRAF
  - RAF1
  - AKT2
  - AKT3
  - AKT1
  - TSC1
  - TSC2
  - CTNNB1
  - PAK5
  - PAK1
  - PAK2
  - PAK3
  - PAK4
  - PAK6
  - MAP2K1
  - MAP2K2
  - MAPK8
  - MAPK9
  - MAPK10
  - RHEB
  - ACTA1
  - ACTA2
  - ACTG1
  - ACTB
  - ACTC1
  - ACTG2
  - MTOR
  - MAPK3
  - MAPK1
  - JUN
  - STK3
  - IL17RB
  - LATS1
  - LATS2
  - TAZ
  - YY1AP1
  - LIN28B
  - MYC
  - EPHA1
  - EPHA2
  - Lapatinib
  - Nilotinib
  - POEverolimus
  - Sirolimus
  - AZD2014
  - Selubmetinib
  - Cobimetinib
  - Schwannoma
  - Meningioma
  - Ependymoma
  - tumors
genes:
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFD
  entrez: '2277'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFB
  entrez: '7423'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: PGF
  entrez: '5228'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFC
  entrez: '7424'
- word: PD-1/PD-LI
  symbol: PD-1
  source: hgnc_alias_symbol
  hgnc_symbol: PDCD1
  entrez: '5133'
- word: PD-1/PD-LIInhibitor
  symbol: PD-1
  source: hgnc_alias_symbol
  hgnc_symbol: PDCD1
  entrez: '5133'
- word: CXCR4
  symbol: CXCR4
  source: hgnc_symbol
  hgnc_symbol: CXCR4
  entrez: '7852'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: CD44
  symbol: CD44
  source: hgnc_symbol
  hgnc_symbol: CD44
  entrez: '960'
- word: PD-L1
  symbol: PD-L1
  source: hgnc_alias_symbol
  hgnc_symbol: CD274
  entrez: '29126'
- word: CXCR4
  symbol: CXCR4
  source: hgnc_symbol
  hgnc_symbol: CXCR4
  entrez: '7852'
- word: РКА
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKACG
  entrez: '5568'
- word: РКА
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR1A
  entrez: '5573'
- word: РКА
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR2A
  entrez: '5576'
- word: РКА
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR2B
  entrez: '5577'
- word: РКА
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKACA
  entrez: '5566'
- word: РКА
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKACB
  entrez: '5567'
- word: РКА
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR1B
  entrez: '5575'
- word: SRC
  symbol: SRC
  source: hgnc_symbol
  hgnc_symbol: SRC
  entrez: '6714'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: RAC
  symbol: RAC
  source: bioentities_symbol
  hgnc_symbol: RHOG
  entrez: '391'
- word: RAC
  symbol: RAC
  source: bioentities_symbol
  hgnc_symbol: RAC1
  entrez: '5879'
- word: RAC
  symbol: RAC
  source: bioentities_symbol
  hgnc_symbol: RAC2
  entrez: '5880'
- word: RAC
  symbol: RAC
  source: bioentities_symbol
  hgnc_symbol: RAC3
  entrez: '5881'
- word: FAK
  symbol: FAK
  source: hgnc_alias_symbol
  hgnc_symbol: PTK2
  entrez: '5747'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: АКТ
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: АКТ
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: АКТ
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: TSC1/2
  symbol: TSC1
  source: hgnc_symbol
  hgnc_symbol: TSC1
  entrez: '7248'
- word: TSC1/2
  symbol: TSC2
  source: hgnc_symbol
  hgnc_symbol: TSC2
  entrez: '7249'
- word: B-Catenin
  symbol: BCATENIN
  source: bioentities_symbol
  hgnc_symbol: CTNNB1
  entrez: '1499'
- word: PAK
  symbol: PAK
  source: bioentities_symbol
  hgnc_symbol: PAK5
  entrez: '57144'
- word: PAK
  symbol: PAK
  source: bioentities_symbol
  hgnc_symbol: PAK1
  entrez: '5058'
- word: PAK
  symbol: PAK
  source: bioentities_symbol
  hgnc_symbol: PAK2
  entrez: '5062'
- word: PAK
  symbol: PAK
  source: bioentities_symbol
  hgnc_symbol: PAK3
  entrez: '5063'
- word: PAK
  symbol: PAK
  source: bioentities_symbol
  hgnc_symbol: PAK4
  entrez: '10298'
- word: PAK
  symbol: PAK
  source: bioentities_symbol
  hgnc_symbol: PAK6
  entrez: '56924'
- word: МЕК
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: МЕК
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: JNK
  symbol: JNK
  source: bioentities_symbol
  hgnc_symbol: MAPK8
  entrez: '5599'
- word: JNK
  symbol: JNK
  source: bioentities_symbol
  hgnc_symbol: MAPK9
  entrez: '5601'
- word: JNK
  symbol: JNK
  source: bioentities_symbol
  hgnc_symbol: MAPK10
  entrez: '5602'
- word: RHEB
  symbol: RHEB
  source: hgnc_symbol
  hgnc_symbol: RHEB
  entrez: '6009'
- word: Actin
  symbol: Actin
  source: bioentities_symbol
  hgnc_symbol: ACTA1
  entrez: '58'
- word: Actin
  symbol: Actin
  source: bioentities_symbol
  hgnc_symbol: ACTA2
  entrez: '59'
- word: Actin
  symbol: Actin
  source: bioentities_symbol
  hgnc_symbol: ACTG1
  entrez: '71'
- word: Actin
  symbol: Actin
  source: bioentities_symbol
  hgnc_symbol: ACTB
  entrez: '60'
- word: Actin
  symbol: Actin
  source: bioentities_symbol
  hgnc_symbol: ACTC1
  entrez: '70'
- word: Actin
  symbol: Actin
  source: bioentities_symbol
  hgnc_symbol: ACTG2
  entrez: '72'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: JUN
  symbol: JUN
  source: hgnc_symbol
  hgnc_symbol: JUN
  entrez: '3725'
- word: B-Catenin
  symbol: BCATENIN
  source: bioentities_symbol
  hgnc_symbol: CTNNB1
  entrez: '1499'
- word: MST2
  symbol: MST2
  source: hgnc_alias_symbol
  hgnc_symbol: STK3
  entrez: '6788'
- word: CRL4
  symbol: CRL4
  source: hgnc_alias_symbol
  hgnc_symbol: IL17RB
  entrez: '55540'
- word: LATS1/2
  symbol: LATS1
  source: hgnc_symbol
  hgnc_symbol: LATS1
  entrez: '9113'
- word: LATS1/2
  symbol: LATS2
  source: hgnc_symbol
  hgnc_symbol: LATS2
  entrez: '26524'
- word: YAP/TAZ
  symbol: TAZ
  source: hgnc_symbol
  hgnc_symbol: TAZ
  entrez: '6901'
- word: YAP/TAZ
  symbol: YAP
  source: hgnc_alias_symbol
  hgnc_symbol: YY1AP1
  entrez: '55249'
- word: LATS1/2
  symbol: LATS1
  source: hgnc_symbol
  hgnc_symbol: LATS1
  entrez: '9113'
- word: LATS1/2
  symbol: LATS2
  source: hgnc_symbol
  hgnc_symbol: LATS2
  entrez: '26524'
- word: LIN28B
  symbol: LIN28B
  source: hgnc_symbol
  hgnc_symbol: LIN28B
  entrez: '389421'
- word: MYC
  symbol: MYC
  source: hgnc_symbol
  hgnc_symbol: MYC
  entrez: '4609'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: Eph
  symbol: EPH
  source: hgnc_alias_symbol
  hgnc_symbol: EPHA1
  entrez: '2041'
- word: EphA2
  symbol: EPHA2
  source: hgnc_symbol
  hgnc_symbol: EPHA2
  entrez: '1969'
- word: EPH
  symbol: EPH
  source: hgnc_alias_symbol
  hgnc_symbol: EPHA1
  entrez: '2041'
chemicals:
- word: Lapatinib
  source: MESH
  identifier: C490728
- word: Nilotinib
  source: MESH
  identifier: C498826
- word: POEverolimus
  source: ''
  identifier: ''
- word: Sirolimus
  source: MESH
  identifier: D020123
- word: AZD2014
  source: MESH
  identifier: C585537
- word: Selubmetinib
  source: ''
  identifier: ''
- word: Cobimetinib
  source: MESH
  identifier: C574276
diseases:
- word: Schwannoma
  source: MESH
  identifier: D009442
- word: Meningioma
  source: MESH
  identifier: D008577
- word: Ependymoma
  source: MESH
  identifier: D004806
- word: tumors
  source: MESH
  identifier: D009369
figid_alias: PMC7038792__F1
redirect_from: /figures/PMC7038792__F1
figtype: Figure
---
